ONCUSP THERAPEUTICS
OnCusp Therapeutics is a biopharmaceutical company turning cutting-edge research assets into innovative oncology treatments. It is always working to improve the largest value inflection point in the drug development value chain, believing that speeding oncology medication innovation is the most effective method to provide help and hope to cancer patients around the world. It is founded by Bing Yuan, Eric Slosberg, and Andy Fu.
ONCUSP THERAPEUTICS
Industry:
Biotechnology Health Care Pharmaceutical Product Research
Website Url:
http://www.oncusptx.com
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible
Similar Organizations
Allovate Therapeutics
Allovate Therapeutics is a biopharmaceutical company dedicated to making allergy treatment easier.
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
Duopharma Biotech
Duopharma Biotech is pharmaceutical company in Malaysia that provides quality and innovative solutions.
EpiVax
EpiVax is an immunology company developing comprehensive analytical capabilities in the field of computational immunology.
Gankill Pharmaceutical
Gankill Pharma Co., Ltd. is conducting research on cancer treatment drugs using PSMD10.
Harm Reduction Therapeutics
Harm Reduction Therapeutics is a nonprofit pharmaceutical company advancing harm reduction therapies to promote public health.
iuvo Therapeutics
iuvo Therapeutics is a pharmaceutical company focused on providing a portfolio of medical cannabis products for European patients.
Kupando
Kupando is a biopharmaceutical company that develops agonists to stimulates innate immunity.
Mast Therapeutics
Mast Therapeutics is a biopharmaceutical company developing novel, clinical-stage therapies for serious or life-threatening diseases.
Rx-Pharma
Rx Pharma is a Pharmaceutical marketing research and regulatory affairs consultancy based in Ghana.
Spinotech
Spinotech offers the biotechnology, pharmaceutical, and medical technology industries with solutions to increase online visibility.
SuperNemos
SuperNemos is a biological control product containing microscopic beneficial nematodes.
Uteron Pharma
At Uteron pharma they are committed to enabling (cutting-edge scientific) research that is driven by the womenโs needs.
Current Employees Featured
Founder
Official Site Inspections
http://www.oncusptx.com
- Host name: 172.67.72.242
- IP address: 172.67.72.242
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "OnCusp Therapeutics"
OnCusp Therapeutics
Jun 13, 2024 OnCusp Therapeutics is a global biopharmaceutical company translating a focused portfolio of first-in-class oncology assets from promising research into proven medicines. The company is led by a founding team that โฆSee details»
OnCusp Therapeutics - Crunchbase Company Profile
OnCusp Therapeutics is a biopharmaceutical company turning cutting-edge research assets into innovative oncology treatments. It is always working to improve the largest value inflection point in the drug development value chain, โฆSee details»
OnCusp Therapeutics - LinkedIn
OnCusp Therapeutics, Inc., headquartered in New York City, is a biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for ...See details»
OnCusp Therapeutics Commences Operations to Advance โฆ
Jun 30, 2021 The World Health Organization (WHO) released its latest estimates showing that the global cancer burden has risen to 19.3 million new cases and 10.0 million deaths in 2020, โฆSee details»
OnCusp Therapeutics Commences Operations to Advance โฆ
Apr 1, 2021 The World Health Organization ... To learn more information about OnCusp, please visit: www.oncusptx.com [1] Latest global cancer data: Cancer burden rises to 19.3 million new โฆSee details»
OnCusp Therapeutics - VentureRadar
Website: https://www.oncusptx.com/ Develops innovative preclinical ideas into clinically validated treatments for cancer patients, notably CUSP06, a promising ADC ...See details»
OnCusp Therapeutics - PitchBook
OnCusp Therapeutics General Information Description. Developer of innovative oncology therapies designed to innovate treatments that deliver help and hope to cancer patients โฆSee details»
OnCusp - Overview, News & Similar companies | ZoomInfo.com
Jan 3, 2024 OnCusp contact info: Phone number: (646) 585-2168 Website: www.oncusptx.com What does OnCusp do? OnCusp Therapeutics is a global biopharmaceutical company โฆSee details»
OnCusp Therapeutics Commences Operations to Advance โฆ
The World Health Organization (WHO) released its latest estimates showing that the global cancer burden has risen to 19.3 million new cases and 10.0 million deaths in 2020, with one in โฆSee details»
OnCusp Therapeutics Commences Operations to Advance
OnCusp Therapeutics Commences Operations to Advance ... - BioSpaceSee details»
Company News-OnCusp Therapeutics
Jan 04, 2024. OnCusp Therapeutics Raises Oversubscribed $100 Million Series A Financing to Advance Portfolio of Assets for Cancer Patients. Learn moreSee details»
OnCusp Therapeutics Showcases Potent Anti-Tumor ... - Markets โฆ
SHENZHEN, China, April 11, 2023 /PRNewswire/ -- OnCusp Therapeutics, a global biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into โฆSee details»
How Does OnCusp Therapeutics Work? โ CBM
2 days ago Website: https://www.oncusptx.com; Description: OnCusp Therapeutics is a biopharmaceutical company turning cutting-edge research assets into innovative oncology โฆSee details»
OnCusp Therapeutics | ้ข่ฑ - ้ข่ฑ (ไธญๅฝ)
OnCusp Therapeutics | ๅจ้ข่ฑไธๆ 1,483 ไฝๅ ณๆณจ่ ใWe Bring Oncology Innovation to Life | OnCusp Therapeutics, Inc., headquartered in New York City, is a biopharmaceutical company โฆSee details»
OnCusp Therapeutics Raises Oversubscribed $100 Million Series A ...
Financing led by Novo Holdings, OrbiMed, and F-Prime Capital, with participation by new and current investors. Proceeds to advance CUSP06, the companyโs antibody drug conjugate โฆSee details»
OnCusp Therapeutics Raises Oversubscribed $100 Million Series A ...
Jan 4, 2024 Financing led by Novo Holdings, OrbiMed, and F-Prime Capital, with participation by new and current investors; Proceeds to advance CUSP06, the company's antibody drug โฆSee details»
OnCusp Therapeutics Showcases Potent Anti-Tumor Activity of its โฆ
NEW YORK, April 11, 2023 /PRNewswire/ -- OnCusp Therapeutics, a global biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated โฆSee details»
Careers-OnCusp Therapeutics
Headquartered in New York City, OnCusp Therapeutics is transforming a growing portfolio of leading-edge molecules on the cusp of becoming innovative treatments to deliver hope to โฆSee details»
Mission, Vision & Core Values of OnCusp Therapeutics
2 days ago Integrity, innovation, collaboration, and patient-centricity are at the heart of our organization. We believe in conducting our business with the highest ethical standards, โฆSee details»